1.8Å X-ray structure of C95M/C1095F double mutant of tethered HIV-1 protease dimer complexed with acetyl pepstatin
- 17 September 2004
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 323 (4) , 1229-1235
- https://doi.org/10.1016/j.bbrc.2004.08.226
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor TreatmentsJournal of Virology, 2003
- Reversible Oxidative Modification as a Mechanism for Regulating Retroviral Protease Dimerization and ActivationJournal of Virology, 2003
- A Major Role for a Set of Non-Active Site Mutations in the Development of HIV-1 Protease Drug ResistanceBiochemistry, 2003
- Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphologyAntimicrobial Agents and Chemotherapy, 1997
- Regulation of HIV-1 Protease Activity through Cysteine ModificationBiochemistry, 1996
- Reactivity of Cysteine Residues in the Protease from Human Immunodeficiency Virus: Identification of a Surface-Exposed Region Which Affects Enzyme FunctionArchives of Biochemistry and Biophysics, 1993
- Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms.Proceedings of the National Academy of Sciences, 1991
- Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer.Proceedings of the National Academy of Sciences, 1990
- Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.Proceedings of the National Academy of Sciences, 1988
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988